Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ Israel · Middle East & Africa
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Feb 2026: Ibex announced a leadership change, with COO Yair Heller becoming CEO and co-founder Joseph Mossel moving to lead its biopharma division and US clinical growth. No lawsuits, regulator action or financial distress found in HSH's search of the last 24 months.
No data breaches, cyber incidents or regulator action involving Ibex Medical Analytics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
No recalls, FDA/MHRA safety notices or warning letters involving Ibex Medical Analytics found in HSH's search of the last 24 months.
No dated go-lives, troubled implementations, terminations or disputes involving Ibex Medical Analytics found in HSH's search of the last 24 months; Feb 2026 company materials cite deployments with two large European laboratory networks.
No competitors linked yet.